[Critical remarks on gonorrhea therapy: netilmicin].

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Increasing antibiotic resistance in Neisseria gonorrhoeae, including penicillinase-producing strains (PPNG), necessitates novel treatment strategies.
• Established gonorrhea treatments face challenges due to resistance, side effects, and patient compliance issues.
• Modern aminoglycosides, like Netilmicin, show potential with no observed early resistance development.

Purpose of the Study:

• To evaluate the efficacy and safety of a single-dose Netilmicin regimen for uncomplicated gonorrhea.
• To assess Netilmicin as a potential alternative treatment for gonorrhea, addressing current therapeutic limitations.

Main Methods:

• A single intramuscular dose of 300 mg Netilmicin was administered to 600 patients with culture-confirmed uncomplicated gonorrhea.
• Treatment efficacy was assessed through follow-up cultures to confirm eradication of the pathogen.
• Clinical cure and adverse events were monitored to evaluate safety and tolerability.

Main Results:

• All 600 patients achieved a clinical cure of gonorrhea.
• Follow-up cultures were negative in all 600 cases, indicating complete eradication of Neisseria gonorrhoeae.
• No significant disadvantages or adverse events were reported in the literature for Netilmicin.

Conclusions:

• A single 300 mg intramuscular dose of Netilmicin is highly effective and safe for treating uncomplicated gonorrhea.
• Netilmicin represents a viable and promising therapeutic option for gonorrhea, particularly in light of rising antibiotic resistance.
• The single-dose administration enhances patient compliance and simplifies treatment protocols.